Treatment with subcutaneous interferon beta-1a plus remdesivir was not superior to treatment with remdesivir alone in a clinical trial that enrolled 969 hospitalized adults with COVID-19 pneumonia in the United States, Japan, Mexico, Singapore and South Korea, the National Institutes of Health reported yesterday. In addition, interferon beta-1a was associated with more adverse events and worse outcomes in patients who required high-flow oxygen. Previous studies have found that many hospitalized patients with severe COVID-19 produce less interferon. Subcutaneous interferon beta-1a is a multiple sclerosis medication. 

Related News Articles

Headline
The New Hampshire Hospital Association and the Foundation for Healthy Communities Sept. 29 received a Power of Associations Gold Award for their efforts during…
Perspective
With fall in full swing, there are two easy steps that individuals can take to protect themselves and their families against illness — get a flu shot and get a…
Headline
In a study of 151 tax-exempt hospitals reported yesterday in JAMA Network Open, 84% updated their charity care policies between 2019 and 2021. Among the…
Headline
Pfizer has submitted a request for the Food and Drug Administration to authorize a 10-microgram booster dose of its bivalent COVID-19 vaccine booster for…
Headline
Health care providers who treat uninsured or underinsured patients with commercially procured bebtelovimab, a COVID-19 monoclonal antibody therapy for…
Headline
The Centers for Medicare & Medicaid Services Friday reopened the comment period for a 2020 interim final rule that set forth certain requirements for…